

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONEE FOR PATENTS DOE: 1450

in 22313-1450	
	III 22313-1430

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/007,343	10/22/2001	David L. Linemeyer	19202DB	3310
210 7	590 09/23/2003			
MERCK ANI			EXAM	INER
P O BOX 2000 RAHWAY, NJ 070650907			ULM, JOHN D	
			ART UNIT	PAPER NUMBER

DATE MAILED: 09/23/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/007,343	LINEMEYER ET AL.			
Office Action Summary	Examiner	Art Unit			
	John D. Ulm	1646			
The MAILING DATE of this communication app	pears on the cover sheet with the	correspondence address			
P riod for Reply	VIC OCT TO EVDIDE 4 MONTH	(e) EDOM			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed. - It they period for mayly specified above, the maximum statutory within the statutory minimum of thinty (30) days, will be considered timely. - If they period for reply is possified above, the maximum statutory period will apply and will expire 38 (x) (MONTH'S from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than there months after the mailing date of this communication, even if timely filed, may reduce any earned patient term adjustment. See 37 CFR 1.704(b). Status					
Responsive to communication(s) filed on	·				
2a)☐ This action is FINAL . 2b)⊠ Th	nis action is non-final.				
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims					
4) ☐ Claim(s) 1-34 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s)is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) 1-34 are subject to restriction and/or election requirement.					
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the	e drawing(s) be held in abeyance. S	See 37 CFR 1.85(a).			
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12)☐ The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
Certified copies of the priority document	ts have been received.				
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received.					
a) in the translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	ry (PTO-413) Paper No(s) Patent Application (PTO-152)			

U.S. Patent and Trademark Office PTOL-326 (Rev. 04-01) Art Unit: 1646

Claims 1 to 34 are pending in the instant application.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1 to 9, 14 and 25 to 28, drawn to an isolated nucleic acid and method of use, classified in class 435, subclass 7.21.
- Claims 10 and 11, drawn to an isolated protein, classified in class 530, subclass 350.
- III. Claims 12 and 13, drawn to an antibody, classified in class 530, subclass 388.22.
- Claims 15 to 18, drawn to a binding assay, classified in class 436, subclass 501.
- Claims 19 to 22 and 29 to 32, drawn to a compound of unspecified chemical or structural constitution, classification undeterminable.
- Claims 23, 24, 33 and 34, drawn to a method of treatment by administering a compound of unspecified constitution, classification undeterminable.

The inventions are distinct, each from the other because of the following reasons:

The nucleic acid of invention I, the protein of invention II, the antibody of invention III and the compound of invention V are five chemically and structurally different compounds each of which can be made and used without the others. They are shown to be distinct because they lack a common utility that is based upon a shared feature or combination of features lacking from the prior art.

3

Application/Control Number: 10/007,343

Art Unit: 1646

Inventions II and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the binding assay, as claimed, can be practiced with a cell that naturally produces a receptor protein of the instant invention, and the isolated protein, as claimed, can be employed as an immunogen in a process of preparing an antibody thereto.

Inventions V and VI are also related as product and process of use. They are shown to be distinct because the compound, as claimed, can be employed in a materially different process such as in the detection of a receptor thereto in a sample.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/007,343

Art Unit: 1646

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (703) 308-4008. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242 or (703) 872-9306. Official responses under 37 C.F.R. § 1.116 should be directed to (703) 872-9307. Any inquiry of a general nature or relating to the status of this application should

be directed to the Group receptionist whose telephone number is (703) 308-0196.

JOHN ULM PRIMARY EXAMINER GROUP 1990